These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 18304612

  • 1. Refractory central nervous system vasculitis and gastrocnemius myalgia syndrome in Crohn's disease successfully treated with anti-tumor necrosis factor-alpha antibody.
    Ullrich S, Schinke S, Both M, Knop KC, Kirkiles-Smith NC, Gross WL, Lamprecht P.
    Semin Arthritis Rheum; 2009 Apr; 38(5):337-47. PubMed ID: 18304612
    [Abstract] [Full Text] [Related]

  • 2. Adalimumab-induced lupus erythematosus with central nervous system involvement in a patient with Crohn's disease.
    Vannucchi V, Grazzini M, Pieralli F, Giannotta M, Biagioni C, Nozzoli C.
    J Gastrointestin Liver Dis; 2011 Jun; 20(2):201-3. PubMed ID: 21725519
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of tumor necrosis factor alpha blockade in primary central nervous system vasculitis resistant to immunosuppressive treatment.
    Salvarani C, Brown RD, Calamia KT, Huston J, Meschia JF, Giannini C, Miller DV, Hunder GG.
    Arthritis Rheum; 2008 Feb 15; 59(2):291-6. PubMed ID: 18240197
    [No Abstract] [Full Text] [Related]

  • 4. Crohn's disease and gastrocnemius vasculitis: two new cases.
    Disdier P, Swiader L, Harlé JR, Pellissier JF, Figarella-Branger D, Veit V, Gérolami A, Arlet Ph, Weiller PJ.
    Am J Gastroenterol; 1997 May 15; 92(5):880-2. PubMed ID: 9149206
    [Abstract] [Full Text] [Related]

  • 5. Education and imaging. Gastrointestinal: Improvement of granuloma annulare with anti-tumour necrosis factor alpha therapy for Crohn's disease.
    Fanning SB, Chapman G, Yau Y, Leong RW.
    J Gastroenterol Hepatol; 2010 Jan 15; 25(1):215. PubMed ID: 20136975
    [No Abstract] [Full Text] [Related]

  • 6. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.
    Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P.
    Gastroenterology; 2008 Nov 15; 135(5):1493-9. PubMed ID: 18848553
    [Abstract] [Full Text] [Related]

  • 7. Infliximab use in luminal Crohn's disease.
    Richter JA, Bickston SJ.
    Gastroenterol Clin North Am; 2006 Dec 15; 35(4):775-93. PubMed ID: 17129813
    [Abstract] [Full Text] [Related]

  • 8. Anti tumour necrosis factor as risk factor for free perforations in Crohn's disease? A case-control study.
    Eshuis EJ, Griffioen GH, Stokkers PC, Ubbink DT, Bemelman WA.
    Colorectal Dis; 2012 May 15; 14(5):578-84. PubMed ID: 21848898
    [Abstract] [Full Text] [Related]

  • 9. How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease.
    Sandborn WJ.
    Rev Gastroenterol Disord; 2004 May 15; 4 Suppl 3():S25-33. PubMed ID: 15583528
    [Abstract] [Full Text] [Related]

  • 10. Histologically confirmed case of cerebral vasculitis associated with Crohn's disease--a case report.
    Gekka M, Sugiyama T, Nomura M, Kato Y, Nishihara H, Asaoka K.
    BMC Neurol; 2015 Sep 21; 15():169. PubMed ID: 26390922
    [Abstract] [Full Text] [Related]

  • 11. Localised gastrocnemius myositis in Crohn's disease.
    Christopoulos C, Savva S, Pylarinou S, Diakakis A, Papavassiliou E, Economopoulos P.
    Clin Rheumatol; 2003 May 21; 22(2):143-5. PubMed ID: 12740681
    [Abstract] [Full Text] [Related]

  • 12. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM, Krauss N, Voll RE, Nägel A, Weidenhiller M, Konturek PC, Hahn EG, Raithel M.
    Digestion; 2008 May 21; 78(4):195-200. PubMed ID: 19122456
    [Abstract] [Full Text] [Related]

  • 13. Severe cardiomyopathy following treatment with the tumour necrosis factor-alpha inhibitor adalimumab for Crohn's disease.
    Emmert MY, Salzberg SP, Emmert LS, Behjati S, Plass A, Felix C, Falk V, Gruenenfelder J.
    Eur J Heart Fail; 2009 Nov 21; 11(11):1106-9. PubMed ID: 19875411
    [Abstract] [Full Text] [Related]

  • 14. [Adalimumab therapy in Crohn's disdease].
    Baryshnikov EN, Lazebnik LB, Parfenov AI.
    Eksp Klin Gastroenterol; 2009 Nov 21; (5):92-8. PubMed ID: 20205331
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW, Lawrance IC.
    J Gastroenterol Hepatol; 2009 Jul 21; 24(7):1252-7. PubMed ID: 19220669
    [Abstract] [Full Text] [Related]

  • 16. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
    Rozpondek P, Zwolińska-Wcisło M, Przybylska M, Mach T.
    Przegl Lek; 2011 Jul 21; 68(9):602-5. PubMed ID: 22335009
    [Abstract] [Full Text] [Related]

  • 17. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
    Lawrance IC, Radford-Smith GL, Bampton PA, Andrews JM, Tan PK, Croft A, Gearry RB, Florin TH.
    J Gastroenterol Hepatol; 2010 Nov 21; 25(11):1732-8. PubMed ID: 21039834
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Perianal fistulas in Crohn's disease--biologicals and surgery: is it worthwhile?].
    Bode M, Eder S, Schürmann G.
    Z Gastroenterol; 2008 Dec 21; 46(12):1376-83. PubMed ID: 19053007
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.